Q-omics provides the consensus-scored RNF19A profile across patient tissues and cancer cell-line models. RNF19A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNF19A is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RNF19A RNA expression shows 21,009 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where RNF19A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF19A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF19A survival associations across molecular data types. RNF19A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF19A RNA expression–survival associations across cancer types. High RNF19A expression shows unfavorable associations in UVM, KIRP, ACC and LUSC, but favorable associations in BLCA and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RNF19A RNA expression.
This table summarizes RNF19A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF19A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF19A shows lower tumor expression in KICH, UCEC and THCA and higher tumor expression in HNSC, STAD and LIHC. The KICH box plot shows higher RNF19A RNA expression in normal versus tumor tissue (log2 FC = −1.794, t-test p < 0.001).
This table shows molecular features associated with RNF19A in patient tissues and cancer cell lines. In patient samples, RNF19A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF19A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
